CTLA4 and melanoma: In 2011, the US Food and Drug Administration (FDA) approved the first immune checkpoint inhibitor (ICI) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4 or CD152), after it became the first drug ever shown to improve survival for patients with advanced melanoma [2].